Global CD31 Antibody Market Growth 2023-2029

Global CD31 Antibody Market Growth 2023-2029

The global CD31 Antibody market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

Growing patient base, launch of novel CD31 antibody drugs, increasing penetration of antibody drugs, and continuous regulation across the biopharmaceutical industry are the key factors driving the increase in CD31 antibody market revenue.

CD31 Antibody can be used in a variety of scientific applications, including western blotting, immunohistochemistry, immunocytochemistry, immunoprecipitation, and ELISA. These antibodies target CD31 in human, mouse, rat, rabbit and pig samples.

LPI (LP Information)' newest research report, the “CD31 Antibody Industry Forecast” looks at past sales and reviews total world CD31 Antibody sales in 2022, providing a comprehensive analysis by region and market sector of projected CD31 Antibody sales for 2023 through 2029. With CD31 Antibody sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CD31 Antibody industry.

This Insight Report provides a comprehensive analysis of the global CD31 Antibody landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on CD31 Antibody portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global CD31 Antibody market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CD31 Antibody and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CD31 Antibody.

This report presents a comprehensive overview, market shares, and growth opportunities of CD31 Antibody market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Monoclonal
Polyclonal

Segmentation by application
Immunochemistry (IHC)
Immunofluorescence (IF)
Western Blot (WB)
Immunocytochemistry (ICC)
ELISA
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
BosterBio
Bio-Rad
Bioss
Thermo Fisher Scientific
NSJ Bioreagents
R and D Systems
Abcam
BioLegend
GeneTex
Novus Biologicals
SouthernBiotech
LifeSpan BioSciences
Enzo Life Sciences
Bethyl Laboratories
Abbexa
ProSci
Proteintech
Synaptic Systems
BIOCARE MEDICAL
CUSABIO Technology
Absolute Antibody
EpiGentek
Biorbyt
Wuhan Fine Biotech
Sino Biological

Key Questions Addressed in this Report

What is the 10-year outlook for the global CD31 Antibody market?

What factors are driving CD31 Antibody market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do CD31 Antibody market opportunities vary by end market size?

How does CD31 Antibody break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.